作者: Qian Wen , Wen-Ting He , Wei Luo , Shu Chen , Li Ma
DOI:
关键词: Colorectal cancer 、 Bevacizumab 、 Cetuximab 、 T-cell receptor 、 Irinotecan 、 CD8 、 Fluorouracil 、 FOLFIRI 、 Cancer research 、 Medicine
摘要: We have previous found a positive correlation between post-therapy TCR repertoire normalization and remission of colorectal cancer (CRC) patients following fluorouracil, leucovorin, irinotecan (FOLFIRI) plus bevacizumab or Rh-endostatin therapy. To further define the diversity changes treatment in CRC patients, confirm its potential prognostic value, present study extended sample size follow-up used an alternative therapy regime to investigate repertoires Erbitux FOLFIRI Inclusion exclusion criteria been established screen out 26 receive Efficacy toxicity assessment made for them after 3 months’ as well has determined. A CDR3 complex scoring system was quantify repertoire. The results showing that CD4+ T cells PR group significantly higher than SD PD groups, difference enlargement treatment. CD8+ no before treatment, but significant decrease In conclusion, analysis cell important prognosis value patients.